Relationship Between Serum N/OFQ and Acute Myeloid Cell Leukemia
NCT ID: NCT06469047
Last Updated: 2024-06-21
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
NOT_YET_RECRUITING
80 participants
OBSERVATIONAL
2024-06-20
2024-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Multicenter Prospective Cohort Study Study of CLAG Regimen in Acute Myeloid Leukemia Patients With First-induction Failure
NCT05875649
A Phase I Study of AC220 in Patients With Relapsed/Refractory Acute Myeloid Leukemia Regardless of FLT3 Status
NCT00462761
Analysis of CMTM6 Expression in Patients With Acute Myeloid Leukemia
NCT05988047
Reduced-Dose Chemo Followed by 14 Days of Blinatumomab for Newly Diagnosed Adult B-ALL Patients: a Multicenter Study
NCT06649422
Studying Biomarkers in Samples From Younger Patients With Acute Myeloid Leukemia
NCT01642121
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
CROSS_SECTIONAL
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
the newly diagnosed group
Enzyme-linked immunosorbent assay
Serum N/OFQ , IL-1β and NE levels were detected.
the relapsed group
Enzyme-linked immunosorbent assay
Serum N/OFQ , IL-1β and NE levels were detected.
the complete remission group
Enzyme-linked immunosorbent assay
Serum N/OFQ , IL-1β and NE levels were detected.
the control group
Enzyme-linked immunosorbent assay
Serum N/OFQ , IL-1β and NE levels were detected.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Enzyme-linked immunosorbent assay
Serum N/OFQ , IL-1β and NE levels were detected.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* No treatment has been received in the past 6 months.
* None of the candidates are related and known this study, and sign the informed consent.
Exclusion Criteria
* People with mental illness or cognitive impairment;
* Patients with infectious diseases; ④Patients with severe heart, liver, kidney and other organ function lesions; ⑤ Combined with other malignant swelling. The tumor.
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Second Hospital of Shanxi Medical University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Zheng Guo
professor
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Second Hospital of Shanxi Medical University
Taiyuan, Shanxi, China
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Hanyi20240408
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.